OIPE JC119 OCT 20 2003 PATENT & TRADEMARK OFFICE

Form PTO-1449

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Attorney Docket No.	Serial No.
820701-1015	**10/671,360**
Applicant: **Powers et al.**	
Filing Date: **September 25, 2003**	Group: **Unknown**

U.S. PATENT DOCUMENTS

Examiner Initials	Item	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
CB	A	5,514,694	5/97	Powers et al.	514	357	6/93
CB	B	5,610,297	3/97	Powers	544	168	10/95
CB	C	5,650,508	7/97	Powers	544	168	10/95
CB	D	6,235,929	5/01	Powers	562	450	12/96

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, etc.)*

CB	1	Dourdin et al. *Reduced Cell Migration and Disruption of the Actin Cytoskeleton in Calpain-deficient Embryonic Fibroblasts.* The Journal of Biological Chemistry, December 21, 2001, Vol. 276, No. 51, pp. 48382-48388.
CB	2	Kohli et al. *Calpain is a mediator of preservation-reperfusion injury in rat liver transplantation.* Proc. Natl. Acad. Sci. USA, Medical Sciences, August 1997, Vol. 94, pp. 9354-9359.
CB	3	Kupina et al. *The Novel Calpain Inhibitor SJA6017 Improves Functional Outcome after Delayed Administration in a Mouse Model of Diffuse Brain Injury.* Journal of Neurotrauma, 2001, Vol. 18, No. 11, pp. 1229-1240.
CB	4	Markgraf et al. *Six-hour Window of Opportunity for Calpain Inhibition in Focal Cerebral Ischemia in Rats.* American Heart Association, Inc., 1998, pp. 152-158.
CB	5	Saatman et al., *Calpain inhibitor AK295 attenuates motor and cognitive deficits following experimental brain injury in the rat.* Proc. Natl. Acad. Sci. USA, Neurobiology, April 1996, Vol. 93, pp. 3428-3433.
CB	6	Schumacher et al. *Pretreatment with Calpain Inhibitor CEP-4143 Inhibits Calpain I Activiation and Cytoskeletal Degradation, Improves Neurological Function, and Enhances Axonal Survival After Traumatic Spinal Cord Injury.* Journal of Neurochemistry, 200, Vol. 74, No. 4, pp.1646-1655.
CB	7	Shields et al. *A punative mechanism of demyelination in multiple sclerosis by a proteolytic enzyme, calpain.* Proc. Natl. Acad. Sci. USA, September 1999, Vol. 96, pp. 11486-11491.

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

EXAMINER'S SIGNATURE:	DATE CONSIDERED:
/Christina Bradley/ (08/08/2006)	

Form PTO-1449	Attorney Docket No. 820701-1015	Serial No. 10/671,360
INFORMATION DISCLOSURE CITATION *(Use several sheets if necessary)*	Applicant **Powers, et al.**	
	Filing Date **09/25/2003**	Group **1614**

PATENT & TRADEMARK OFFICE AUG 05 2004

U.S. PATENT DOCUMENTS

Examiner Initials	Item	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
CB	A	5,760.048	06/02/98	Wang et al.			
CB	B	5,554,767	09/10/96	Want et al.			
	C						
	D						
	E						
	F						
	G						
	H						
	I						
	J						
	K						

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	L							
	M							
	N							
	O							

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, etc.)*

	P	
	Q	
	R	

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

EXAMINER'S SIGNATURE:	DATE CONSIDERED:
/Christina Bradley/ (08/08/2006)	